| AA | AA Amyloidosis |
| AML | Acute myeloid leukemia |
| ANCA | Antineutrophil cytoplasmic antibodies |
| ASCT | Autologous stem cell transplantation |
| CAR-T | Chimeric antigen receptor T-cell therapy |
| CCL5 | C-C motif chemokine ligand 5 |
| CH | Clonal hematopoiesis |
| CHF | Congestive heart failure |
| CHIP | Clonal hematopoiesis of indeterminate potential |
| CVD | Cardiovascular diseases |
| CXCL | C-X-C motif ligand |
| DNMT3A | DNA methyltransferase 3 alpha |
| HSC | Hematopoietic stem cells |
| HIV | Human immunodeficiency virus |
| IMiD | Immunomodulatory drug |
| MDS | Myelodysplastic syndrome |
| MDS-PA | MDS phenotypic alterations |
| MGUS | Monoclonal gammopathy of unknown significance |
| MM | Multiple myeloma |
| NGS | Next Generation Sequencing |
| NHL | Non-Hodgkin lymphoma |
| OS | Overall survival |
| PFS | Progression-free survival |
| PV | Polycythemia vera |
| RA | Rheumatoid arthritis |
| TET2 | Tet methylcytosine dioxygenase 2 |
| tMN | Therapy-related myeloid neoplasms |
| TNF | Tumor necrosis factor |
| UC | Ulcerative colitis |
| VAF | Variant allele frequency |
| WM | Waldenström’s macroglobulinemia |
| WES | Whole exome sequencing |